ReviewPediatric research2026
The role of NLRP3 inflammasome in necrotizing enterocolitis.
Review in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evolving role of mitochondrial dysfunction and mitophagy in necrotizing enterocolitis.Pediatric research · 2026Article
- Role of NLRP3 Inflammasomes in Disorders of Children's Digestive Systems: A Narrative Review.Pediatric reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review explores the association between the NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasomes and necrotizing enterocolitis (NEC) in neonates. It underscores the role of NLRP3 inflammasome overactivation in NEC pathogenesis and proposes that inhibiting NLRP3 inflammasome activation may improve therapeutic benefits. This review examines various strategies to inhibit NLRP3 inflammasome activation, detailing their pharmacological mechanisms. IMPACT: The aim of this review is to discuss the role of NLRP3 inflammasome in the progression of NEC. Abnormal NLRP3 inflammasome activation in patients with NEC and experimental models. Molecules and proteins have been identified as regulators of NLRP3 inflammasome activity, offering avenues for NEC treatment. The NLRP3 inflammasome is a key contributor to NEC. Novel NLRP3 inflammasome inhibitors are the focus of the development of NEC therapeutics.
Indexed as
Identifiers
40473807What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.